Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Cost of Revenue (2021 - 2025)

Oncology Institute (TOI) has disclosed Cost of Revenue for 5 consecutive years, with -$89.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue fell 697.41% year-over-year to -$89.3 million, compared with a TTM value of -$100.7 million through Sep 2025, down 567.18%, and an annual FY2024 reading of $1.3 million, up 125.61% over the prior year.
  • Cost of Revenue was -$89.3 million for Q3 2025 at Oncology Institute, down from $51.1 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $95.6 million in Q2 2024 and bottomed at -$109.7 million in Q4 2024.
  • Average Cost of Revenue over 5 years is $6.8 million, with a median of $14.9 million recorded in 2024.
  • The sharpest move saw Cost of Revenue skyrocketed 39688.5% in 2023, then crashed 697.41% in 2025.
  • Year by year, Cost of Revenue stood at $61.6 million in 2021, then plummeted by 37.7% to $38.4 million in 2022, then crashed by 332.91% to -$89.4 million in 2023, then fell by 22.66% to -$109.7 million in 2024, then grew by 18.61% to -$89.3 million in 2025.
  • Business Quant data shows Cost of Revenue for TOI at -$89.3 million in Q3 2025, $51.1 million in Q2 2025, and $47.1 million in Q1 2025.